Claims:

1. A compound of formula (I)



(I)

or a salt thereof

wherein:

R_1 is C_{1-4}alkyl;

R_2 is C_{1-4}alkyl, C_{3-7}cycloalkyl, $-CH_2CF_3$, $-CH_2OCH_3$ or heterocyclyl;

R_3 is C_{1-4}alkyl, $-CH_2F$, $-CH_2OH$ or $-CH_2OC(O)CH_3$;

R_4 when present is H, hydroxy, halo, cyano, $-CO_2H$, $-CONH_2$, $-OSO_2CF_3$, $-C(O)N(R_8)C_{1-4}$alkyleneOH, $-C(O)N(R_8)C_{1-4}$alkyleneOCH$_3$, $-C(O)N(R_8)C_{1-4}$alkyleneNR$_6$R$_7$, $-C(O)N(R_8)C_{1-4}$alkyleneSO$_2$CH$_3$, $-C(O)N(R_8)C_{1-4}$alkyleneCN, $-C(O)NHOH$, $-C(O)NHCH(CH_2OH)_2$, $-OCH_2CH_2OH$, -B-C_{1-6}alkyl, -B-C_{3-7}cycloalkyl, ~~-B-phenyl,~~or -B-heterocyclyl ~~or -B-heteroaromatic~~, wherein the C_{3-7}cycloalkyl, ~~phenyl,~~or heterocyclyl ~~or heteroaromatic~~ ring is optionally substituted by 1 or 2 substituents independently selected from =O, C_{1-6}alkyl, C_{1-6}alkoxy, halo, $-NH_2$, $-CO_2H$, $-C(O)C_{1-6}$alkyl, $-C(O)NHC_{1-6}$alkyl, cyano, $-CH_2CH_2NHCH_3$, $-CH_2CH_2OH$, $-CH_2CH_2OCH_3$, C_{3-7}cycloalkyl, phenyl, heterocyclyl and heteroaromatic;

R_5 when present is H, halo, hydroxy or C_{1-6}alkoxy;

A is –NH-, -O-, -S-, -SO-, $-SO_2$-, -N(C_{1-4}alkyl)- or –NC(O)(CH_3)-;

B is a bond, -O-, -N(R_8)-, S, -SO-, $-SO_2$-, $-SO_2N(R_8)$-, $-CH_2$-, -C(O)-, $-CO_2$-, -N(R_8)C(O)-, -C(O)N(R_8)-, -C(O)N(R_8)CH_2- or -C(O)N(R_8)CH_2CH_2-;

V is phenyl, heteroaromatic or pyridone any of which may be optionally substituted by 1, 2 or 3 substituents independently selected from C_{1-6}alkyl, fluorine, chlorine, C_{1-6}alkoxy, hydroxy, cyclopropyl, cyano, $-CO_2CH_3$, heterocyclyl, $-CO_2H$, $-CH_2NR_6R_7$, $-NR_6R_7$, $-C(O)NR_6R_7$, $-NR_6C(O)R_7$, $-CF_3$, $-NO_2$, $-CH_2OCH_3$, $-CH_2OH$, $-CH(OH)CH_3$, $-SO_2CH_3$, $-CH_2$heterocyclyl, $-OCH_2CH_2NHC(O)CH_3$, $-OCH_2CH_2OH$, $-OCH_2CH_2NH_2$, -C(O)NHheteroaromatic, $-C(O)NHCH_2$heterocyclyl, $-C(O)NHCH_2CH_2OH$, $-C(O)NHCH_2CH_2NH_2$, $-C(O)NHCH_2CH_2SO_2Me$, $-C(O)NHCH_2CH(OH)CH_3$, -C(O)heterocyclyl and -C(O)NHheterocyclyl, wherein the heterocyclyl ring is optionally substituted by -OH;

R_6, R_7, R_8, R_9 and R_{10} are each independently selected from H and C_{1-4}alkyl;

W is CH or N;

X is C or N;

Y is C or N; and

Z is CH or N;

22. A compound or a pharmaceutically acceptable salt thereof for use according to claim 21 wherein the acute or chronic autoimmune and/or inflammatory condition is psoriasis.

23. A compound or a pharmaceutically acceptable salt thereof for use according to claim 21 wherein the acute or chronic autoimmune and/or inflammatory condition is atopic dermatitis.

24 A compound or a pharmaceutically acceptable salt thereof for use according to claim 21 wherein the acute or chronic autoimmune and/or inflammatory condition is vitiligo.

~~26~~25. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 15, in the manufacture of a medicament for the treatment of ~~diseases or conditions for which a bromodomain inhibitor is indicated.~~

~~27. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 26, wherein the disease or condition is~~ an acute or chronic autoimmune and/or inflammatory condition.

~~28~~26. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim ~~27~~25, wherein the acute or chronic autoimmune and/or inflammatory condition is selected from: rheumatoid arthritis, osteoarthritis, acute gout, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease (Crohn's disease and Ulcerative colitis), asthma, chronic obstructive airways disease, pneumonitis, myocarditis, pericarditis, myositis, eczema, dermatitis (including atopic dermatitis), alopecia, vitiligo, bullous skin diseases, nephritis, vasculitis, hypercholesterolemia, atherosclerosis, Alzheimer's disease, depression, Sjögren's syndrome, sialoadenitis, central retinal vein occlusion, branched retinal vein occlusion, Irvine-Gass syndrome (post cataract and post-surgical), retinitis pigmentosa, pars planitis, birdshot retinochoroidopathy, epiretinal membrane, cystic macular edema, parafoveal telengiectasis, tractional maculopathies, vitreomacular traction syndromes, retinal detachment, neuroretinitis, idiopathic macular edema, retinitis, dry eye (keratoconjunctivitis Sicca), vernal keratoconjunctivitis, atopic keratoconjunctivitis, uveitis (such as anterior uveitis, pan uveitis, posterior uveitis, uveitis-associated macular edema), scleritis, diabetic retinopathy, diabetic macula edema, age-related macular dystrophy, hepatitis, pancreatitis, primary biliary cirrhosis, sclerosing cholangitis, Addison's disease, hypophysitis, thyroiditis, type I diabetes, giant cell arteritis, nephritis including lupus nephritis, vasculitis with organ involvement such as glomerulonephritis, vasculitis including giant cell arteritis, Wegener's granulomatosis, Polyarteritis nodosa, Behcet's disease, Kawasaki disease, Takayasu's Arteritis, pyoderma gangrenosum, vasculitis with organ involvement and acute rejection of transplanted organs.

~~29~~27. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim ~~28~~26, wherein the acute or chronic autoimmune and/or inflammatory condition is psoriasis.

~~30~~28. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim ~~28~~26, wherein the acute or chronic autoimmune and/or inflammatory condition is atopic dermatitis.

~~31~~29. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim ~~28~~26, wherein the acute or chronic autoimmune and/or inflammatory condition is vitiligo.